{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:30:54Z","timestamp":1793316654080,"version":"4.5.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Health-related quality of life (HRQOL) in myasthenia gravis (MG) is frequently decreased. Further, there are many validated clinical scales and questionnaires to evaluate the clinical status in MG. We aimed to determine if there was an improvement in HRQOL following an intensive treatment for MG, identify which demographic and clinical features influenced patients\u2019 HRQOL, and investigate if the questionnaire MG-QOL15 correlated with other evaluation scales. We recruited 45 patients with generalised MG who were starting immunomodulatory treatment with intravenous immunoglobulins and prednisone for the first time. At each visit, we administered several validated scales for MG. The mean MG-QOL15 score improved significantly at 4 and 6 weeks of the study. Additionally, the MG-QOL15 score correlated strong with the Myasthenia Gravis-Activities of Daily Living (MG-ADL) and the Neuro-QOL Fatigue and weakest with the Quantitative Myasthenia Gravis Scoring System (QMG). The QMG score prior to study enrolment was associated with HRQOL. We observed that HRQOL in MG improved after receiving an intensive immunomodulatory treatment and achieving better control of the symptoms. The questionnaire MG-QOL15 correlated positively with other clinical measures. As MG is a fluctuating condition, and some symptoms are difficult to examine, we direct physicians toward the use of scales and questionnaires composed of items perceived by the patient.<\/jats:p>","DOI":"10.3390\/jcm11082189","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T21:44:06Z","timestamp":1649972646000},"page":"2189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-1523","authenticated-orcid":false,"given":"Laura","family":"Diez Porras","sequence":"first","affiliation":[{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute (IDIBELL), 199 Granvia de l\u2019Hospitalet, 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Homedes","sequence":"additional","affiliation":[{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute (IDIBELL), 199 Granvia de l\u2019Hospitalet, 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alberti","sequence":"additional","affiliation":[{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute (IDIBELL), 199 Granvia de l\u2019Hospitalet, 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Neuromuscular Unit, Department of Neurology, Bellvitge University Hospital, Feixa Llarga Street n\/n, 08907 L\u2019Hospitalet del Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-2473","authenticated-orcid":false,"given":"Valentina","family":"Velez Santamaria","sequence":"additional","affiliation":[{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute (IDIBELL), 199 Granvia de l\u2019Hospitalet, 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Neuromuscular Unit, Department of Neurology, Bellvitge University Hospital, Feixa Llarga Street n\/n, 08907 L\u2019Hospitalet del Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute (IDIBELL), 199 Granvia de l\u2019Hospitalet, 08908 L\u2019Hospitalet de Llobregat, Spain"},{"name":"Neuromuscular Unit, Department of Neurology, Bellvitge University Hospital, Feixa Llarga Street n\/n, 08907 L\u2019Hospitalet del Llobregat, Spain"},{"name":"Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, 3\u20135 Monforte de Lemos, Pabell\u00f3n 121, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13497","DOI":"10.1038\/s41598-020-70539-4","article-title":"Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis","volume":"10","author":"Homedes","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mus.21609","article-title":"Construct and concurrent validation of the MG-QOL15 in the practice setting","volume":"41","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/00207454.2015.1038712","article-title":"Quality of life in 188 patients with myasthenia gravis in China","volume":"126","author":"Yang","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mus.26719","article-title":"Severity and depression can impact quality of life in patients with myasthenia gravis","volume":"61","author":"Alanazy","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The Myasthenia Gravis-Specific Activities of Daily Living Profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability Testing of the Quantitative Myasthenia Gravis Score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_14","unstructured":"(2022, March 03). National Institute of Neurological Disorders (NINDS), Available online: https:\/\/www.ninds.nih.gov\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"and M.-O.S. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/mus.26910","article-title":"Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study","volume":"62","author":"McPherson","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6061\/clinics\/2016(07)03","article-title":"Determinants of quality of life in Brazilian patients with myasthenia gravis","volume":"71","author":"Mansueto","year":"2016","journal-title":"Clinics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4103\/0028-3886.181542","article-title":"MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India","volume":"64","author":"Kumar","year":"2016","journal-title":"Neurol. India"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1468-1331.2006.01149.x","article-title":"Correlation between regional myasthenic weakness and mental aspects of quality of life","volume":"13","author":"Rostedt","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: Recommendations for clinical research standards","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann. Thorac. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s100720100066","article-title":"Health-related quality of life in patients with myasthemia gravis and the relationship between patient-oriented assessment and conventional measurements","volume":"22","author":"Padua","year":"2001","journal-title":"Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","article-title":"Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia)","volume":"33","author":"Basta","year":"2012","journal-title":"Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"Romi","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Segovia","year":"2020","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10072-009-0194-8","article-title":"Social support and self-efficacy in patients with Myasthenia Gravis: A common pathway towards positive health outcomes","volume":"31","author":"Raggi","year":"2010","journal-title":"Neurol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"11","author":"Twork","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jnnp-2011-301449","article-title":"Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis","volume":"84","author":"Barnett","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mus.26104","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","volume":"58","author":"Lee","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual. Life Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:53:57Z","timestamp":1760136837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11082189"],"URL":"https:\/\/doi.org\/10.3390\/jcm11082189","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}